<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">jgo</journal-id>
<journal-title-group>
<journal-title>Journal of Gynecologic Oncology</journal-title>
<abbrev-journal-title>J Gynecol Oncol</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2005-0380</issn>
<issn pub-type="epub">2005-0399</issn>
<publisher>
<publisher-name>Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, Japan Society of Gynecologic Oncology</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3802/jgo.2018.29.e83</article-id>
<article-id pub-id-type="publisher-id">jgo-29-e83</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Quality indicators for cervical cancer care in Japan</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Watanabe</surname><given-names>Tomone</given-names></name>
<xref ref-type="aff" rid="aff1-jgo-29-e83"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c1-jgo-29-e83"/>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Mikami</surname><given-names>Mikio</given-names></name>
<xref ref-type="aff" rid="aff2-jgo-29-e83"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Katabuchi</surname><given-names>Hidetaka</given-names></name>
<xref ref-type="aff" rid="aff3-jgo-29-e83"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Kato</surname><given-names>Shingo</given-names></name>
<xref ref-type="aff" rid="aff4-jgo-29-e83"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Kaneuchi</surname><given-names>Masanori</given-names></name>
<xref ref-type="aff" rid="aff5-jgo-29-e83"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Takahashi</surname><given-names>Masahiro</given-names></name>
<xref ref-type="aff" rid="aff6-jgo-29-e83"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Nakai</surname><given-names>Hidekatsu</given-names></name>
<xref ref-type="aff" rid="aff7-jgo-29-e83"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Nagase</surname><given-names>Satoru</given-names></name>
<xref ref-type="aff" rid="aff8-jgo-29-e83"><sup>8</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Niikura</surname><given-names>Hitoshi</given-names></name>
<xref ref-type="aff" rid="aff9-jgo-29-e83"><sup>9</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Mandai</surname><given-names>Masaki</given-names></name>
<xref ref-type="aff" rid="aff10-jgo-29-e83"><sup>10</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Hirashima</surname><given-names>Yasuyuki</given-names></name>
<xref ref-type="aff" rid="aff11-jgo-29-e83"><sup>11</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Yanai</surname><given-names>Hiroyuki</given-names></name>
<xref ref-type="aff" rid="aff12-jgo-29-e83"><sup>12</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Yamagami</surname><given-names>Wataru</given-names></name>
<xref ref-type="aff" rid="aff13-jgo-29-e83"><sup>13</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Kamitani</surname><given-names>Satoru</given-names></name>
<xref ref-type="aff" rid="aff1-jgo-29-e83"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western" xml:lang="en"><surname>Higashi</surname><given-names>Takahiro</given-names></name>
<xref ref-type="aff" rid="aff1-jgo-29-e83"><sup>1</sup></xref>
</contrib>
<aff id="aff1-jgo-29-e83"><label>1</label>Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, <country>Japan</country></aff>
<aff id="aff2-jgo-29-e83"><label>2</label>Department of Obstetrics and Gynecology, Tokai University, Kanagawa, <country>Japan</country></aff>
<aff id="aff3-jgo-29-e83"><label>3</label>Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, <country>Japan</country></aff>
<aff id="aff4-jgo-29-e83"><label>4</label>Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, <country>Japan</country></aff>
<aff id="aff5-jgo-29-e83"><label>5</label>Department of Obstetrics and Gynecology, Otaru General Hospital, Hokkaido, <country>Japan</country></aff>
<aff id="aff6-jgo-29-e83"><label>6</label>Department of Medical Oncology, Tohoku University Hospital, Miyagi, <country>Japan</country></aff>
<aff id="aff7-jgo-29-e83"><label>7</label>Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, <country>Japan</country></aff>
<aff id="aff8-jgo-29-e83"><label>8</label>Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, <country>Japan</country></aff>
<aff id="aff9-jgo-29-e83"><label>9</label>Department of Obstetrics and Gynecology, Tohoku University, Miyagi, <country>Japan</country></aff>
<aff id="aff10-jgo-29-e83"><label>10</label>Department of Gynecology and Obsteterics, Kyoto University Graduate School of Medicine, Kyoto, <country>Japan</country></aff>
<aff id="aff11-jgo-29-e83"><label>11</label>Division of Gynecology, Shizuoka Cancer Center Hospital, Shizuoka, <country>Japan</country></aff>
<aff id="aff12-jgo-29-e83"><label>12</label>Department of Pathology, Okayama University Hospital, Okayama, <country>Japan</country></aff>
<aff id="aff13-jgo-29-e83"><label>13</label>Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, <country>Japan</country></aff>
</contrib-group>
<author-notes>
<corresp id="c1-jgo-29-e83"><bold>Correspondence to</bold> Tomone Watanabe Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan. E-mail: <email>tomonwat@ncc.go.jp</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>04</day>
<month>11</month>
<year>2018</year>
</pub-date>
<volume>29</volume>
<issue>6</issue>
<elocation-id>e83</elocation-id>
<history>
<date date-type="received"><day>06</day><month>10</month><year>2017</year></date>
<date date-type="rev-recd"><day>09</day><month>07</month><year>2018</year></date>
<date date-type="accepted"><day>09</day><month>07</month><year>2018</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2018 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology</copyright-statement>
<copyright-year>2018</copyright-year>
<license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license>
</permissions>
<abstract xml:lang="en">
<title>Abstract</title>
<sec>
<title>Objective</title>
<p>We aimed to propose a set of quality indicators (QIs) based on the clinical guidelines for cervical cancer treatment published by The Japan Society of Gynecologic Oncology, and to assess adherence to standard-of-care as an index of the quality of care for cervical cancer in Japan.</p>
</sec>
<sec>
<title>Methods</title>
<p>A panel of clinical experts devised the QIs using a modified Delphi method. Adherence to each QI was evaluated using data from a hospital-based cancer registry of patients diagnosed in 2013, and linked with insurance claims data, between October 1, 2012, and December 31, 2014. All patients who received first-line treatment at the participating facility were included. The QI scores were communicated to participating hospitals, and additional data about the reasons for non-adherence were collected.</p>
</sec>
<sec>
<title>Results</title>
<p>In total, 297 hospitals participated, and the care provided to 15,163 cervical cancer patients was examined using 10 measurable QIs. The adherence rate ranged from 50.0&#x0025; for &#x2018;cystoscope or proctoscope for stage IVA&#x0027; to 98.8&#x0025; for &#x2018;chemotherapy using platinum for stage IVB&#x0027;. Despite the variation in care, hospitals reported clinically valid reasons for more than half of the non-adherent cases. Clinically valid reasons accounted for 75&#x0025;, 90.9&#x0025;, 73.4&#x0025;, 44.5&#x0025;, and 88.1&#x0025; of presented non-adherent cases respectively.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Our study revealed variations in pattern of care as well as an adherence to standards-of-care across Japan. Further assessment of the causes of variation and non-adherence can help identify areas where improvements are needed in patient care.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<kwd>Quality Indicators</kwd>
<kwd>Uterine Cervical Neoplasms</kwd>
<kwd>Standard of Care</kwd>
<kwd>Guideline Adherence</kwd>
<kwd>Practice Guideline</kwd>
</kwd-group>
</article-meta>
</front>
<back>
<ref-list xml:lang="en">
<title>References</title>
<ref id="b1-jgo-29-e83"><label>1</label><element-citation publication-type="book"><collab>International Agency for Research on Cancer</collab> <source>GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]</source> <publisher-loc>Lyon</publisher-loc> <publisher-name>International Agency for Research on Cancer</publisher-name> <year>2012</year> <comment>[cited 2017 Jun 30]. Available from:</comment> <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp">http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp</ext-link></element-citation></ref>
<ref id="b2-jgo-29-e83"><label>2</label><element-citation publication-type="journal"><collab>National Institutes of Health Consensus Development Conference statement on cervical cancer</collab> <article-title>April 1&#x2013;3, 1996</article-title> <source>Gynecol Oncol</source> <year>1997</year> <volume>66</volume> <fpage>351</fpage><lpage>61</lpage></element-citation></ref>
<ref id="b3-jgo-29-e83"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname> <given-names>M</given-names></name> <name><surname>Matsuda</surname> <given-names>T</given-names></name> <name><surname>Shibata</surname> <given-names>A</given-names></name> <name><surname>Katanoda</surname> <given-names>K</given-names></name> <name><surname>Sobue</surname> <given-names>T</given-names></name> <name><surname>Nishimoto</surname> <given-names>H</given-names></name>, <etal/></person-group> <article-title>Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project</article-title> <source>Jpn J Clin Oncol</source> <year>2015</year> <volume>45</volume> <fpage>884</fpage><lpage>91</lpage></element-citation></ref>
<ref id="b4-jgo-29-e83"><label>4</label><element-citation publication-type="book"><collab>National Cancer Center</collab> <source>National database of hospital-based cancer registries: 5 year survival report 2008 [Internet]</source> <publisher-loc>Tokyo</publisher-loc> <publisher-name>National Cancer Center</publisher-name> <year>2017</year> <comment>Aug [cited 2018 Jul 2]. Available from:</comment> <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ganjoho.jp/data/reg_stat/statistics/brochure/hosp_c_reg_surv_2008.pdf">https://ganjoho.jp/data/reg_stat/statistics/brochure/hosp_c_reg_surv_2008.pdf</ext-link></element-citation></ref>
<ref id="b5-jgo-29-e83"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagami</surname> <given-names>W</given-names></name> <name><surname>Nagase</surname> <given-names>S</given-names></name> <name><surname>Takahashi</surname> <given-names>F</given-names></name> <name><surname>Ino</surname> <given-names>K</given-names></name> <name><surname>Hachisuga</surname> <given-names>T</given-names></name> <name><surname>Aoki</surname> <given-names>D</given-names></name>, <etal/></person-group> <article-title>Clinical statistics of gynecologic cancers in Japan</article-title> <source>J Gynecol Oncol</source> <year>2017</year> <volume>28</volume> <fpage>e32</fpage></element-citation></ref>
<ref id="b6-jgo-29-e83"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujikawa</surname> <given-names>K</given-names></name> <name><surname>Miyamoto</surname> <given-names>T</given-names></name> <name><surname>Ihara</surname> <given-names>Y</given-names></name> <name><surname>Matsui</surname> <given-names>Y</given-names></name> <name><surname>Takeuchi</surname> <given-names>H</given-names></name></person-group> <article-title>High incidence of severe urologic complications following radiotherapy for cervical cancer in Japanese women</article-title> <source>Gynecol Oncol</source> <year>2001</year> <volume>80</volume> <fpage>21</fpage><lpage>3</lpage></element-citation></ref>
<ref id="b7-jgo-29-e83"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabuchi</surname> <given-names>S</given-names></name> <name><surname>Okazawa</surname> <given-names>M</given-names></name> <name><surname>Isohashi</surname> <given-names>F</given-names></name> <name><surname>Matsuo</surname> <given-names>K</given-names></name> <name><surname>Ohta</surname> <given-names>Y</given-names></name> <name><surname>Suzuki</surname> <given-names>O</given-names></name>, <etal/></person-group> <article-title>Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer</article-title> <source>Gynecol Oncol</source> <year>2011</year> <volume>123</volume> <fpage>241</fpage><lpage>7</lpage></element-citation></ref>
<ref id="b8-jgo-29-e83"><label>8</label><element-citation publication-type="book"><collab>Institute of Medicine Committee on Quality of Health Care in America</collab> <source>Crossing the quality chasm: a new health system for the 21st century</source> <publisher-loc>Washington, D.C.</publisher-loc> <publisher-name>National Academies Press (US)</publisher-name> <year>2001</year></element-citation></ref>
<ref id="b9-jgo-29-e83"><label>9</label><element-citation publication-type="book"><collab>Ministry of Health, Labour and Welfare</collab> <source>Overview of the &#x201C;Cancer Control Act&#x201D; [Internet]</source> <publisher-loc>Tokyo</publisher-loc> <publisher-name>Ministry of Health, Labour and Welfare</publisher-name> <year>2012</year> <comment>[cited 2017 Jun 20]. Available from:</comment> <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.mhlw.go.jp/english/wp/wp-hw3/dl/2-077.pdf">http://www.mhlw.go.jp/english/wp/wp-hw3/dl/2-077.pdf</ext-link><comment>;</comment><ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.mhlw.go.jp/bunya/kenkou/dl/gan_keikaku02.pdf">http://www.mhlw.go.jp/bunya/kenkou/dl/gan_keikaku02.pdf</ext-link></element-citation></ref>
<ref id="b10-jgo-29-e83"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagase</surname> <given-names>S</given-names></name> <name><surname>Inoue</surname> <given-names>Y</given-names></name> <name><surname>Umesaki</surname> <given-names>N</given-names></name> <name><surname>Aoki</surname> <given-names>D</given-names></name> <name><surname>Ueda</surname> <given-names>M</given-names></name> <name><surname>Sakamoto</surname> <given-names>H</given-names></name>, <etal/></person-group> <article-title>Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition</article-title> <source>Int J Clin Oncol</source> <year>2010</year> <volume>15</volume> <fpage>117</fpage><lpage>24</lpage></element-citation></ref>
<ref id="b11-jgo-29-e83"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebina</surname> <given-names>Y</given-names></name> <name><surname>Yaegashi</surname> <given-names>N</given-names></name> <name><surname>Katabuchi</surname> <given-names>H</given-names></name> <name><surname>Nagase</surname> <given-names>S</given-names></name> <name><surname>Udagawa</surname> <given-names>Y</given-names></name> <name><surname>Hachisuga</surname> <given-names>T</given-names></name>, <etal/></person-group> <article-title>Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer</article-title> <source>Int J Clin Oncol</source> <year>2015</year> <volume>20</volume> <fpage>240</fpage><lpage>8</lpage></element-citation></ref>
<ref id="b12-jgo-29-e83"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fitch</surname> <given-names>K</given-names></name> <name><surname>Bernstein</surname> <given-names>SJ</given-names></name> <name><surname>Aguilar</surname> <given-names>MD</given-names></name> <name><surname>Burnand</surname> <given-names>B</given-names></name> <name><surname>LaCalle</surname> <given-names>JR</given-names></name> <name><surname>L&#x00E1;zaro</surname> <given-names>P</given-names></name>, <etal/></person-group> <source>The RAND/UCLA appropriateness method user&#x0027;s manual [Internet]</source> <publisher-loc>Santa Monica, CA</publisher-loc> <publisher-name>RAND</publisher-name> <year>2001</year> <comment>[cited 2017 Jun 20]. Available from:</comment> <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rand.org/pubs/monograph_reports/MR1269.html">https://www.rand.org/pubs/monograph_reports/MR1269.html</ext-link></element-citation></ref>
<ref id="b13-jgo-29-e83"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashi</surname> <given-names>T</given-names></name> <name><surname>Nakamura</surname> <given-names>F</given-names></name> <name><surname>Shibata</surname> <given-names>A</given-names></name> <name><surname>Emori</surname> <given-names>Y</given-names></name> <name><surname>Nishimoto</surname> <given-names>H</given-names></name></person-group> <article-title>The national database of hospital-based cancer registries: a nationwide infrastructure to support evidence-based cancer care and cancer control policy in Japan</article-title> <source>Jpn J Clin Oncol</source> <year>2014</year> <volume>44</volume> <fpage>2</fpage><lpage>8</lpage></element-citation></ref>
<ref id="b14-jgo-29-e83"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwamoto</surname> <given-names>M</given-names></name> <name><surname>Nakamura</surname> <given-names>F</given-names></name> <name><surname>Higashi</surname> <given-names>T</given-names></name></person-group> <article-title>Monitoring and evaluating the quality of cancer care in Japan using administrative claims data</article-title> <source>Cancer Sci</source> <year>2016</year> <volume>107</volume> <fpage>68</fpage><lpage>75</lpage></element-citation></ref>
<ref id="b15-jgo-29-e83"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trimble</surname> <given-names>EL</given-names></name> <name><surname>Harlan</surname> <given-names>LC</given-names></name> <name><surname>Gius</surname> <given-names>D</given-names></name> <name><surname>Stevens</surname> <given-names>J</given-names></name> <name><surname>Schwartz</surname> <given-names>SM</given-names></name></person-group> <article-title>Patterns of care for women with cervical cancer in the United States</article-title> <source>Cancer</source> <year>2008</year> <volume>113</volume> <fpage>743</fpage><lpage>9</lpage></element-citation></ref>
<ref id="b16-jgo-29-e83"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keys</surname> <given-names>HM</given-names></name> <name><surname>Bundy</surname> <given-names>BN</given-names></name> <name><surname>Stehman</surname> <given-names>FB</given-names></name> <name><surname>Muderspach</surname> <given-names>LI</given-names></name> <name><surname>Chafe</surname> <given-names>WE</given-names></name> <name><surname>Suggs</surname> <given-names>CL</given-names> <suffix>3rd</suffix></name>, <etal/></person-group> <article-title>Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma</article-title> <source>N Engl J Med</source> <year>1999</year> <volume>340</volume> <fpage>1154</fpage><lpage>61</lpage></element-citation></ref>
<ref id="b17-jgo-29-e83"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname> <given-names>M</given-names></name> <name><surname>Eifel</surname> <given-names>PJ</given-names></name> <name><surname>Lu</surname> <given-names>J</given-names></name> <name><surname>Grigsby</surname> <given-names>PW</given-names></name> <name><surname>Levenback</surname> <given-names>C</given-names></name> <name><surname>Stevens</surname> <given-names>RE</given-names></name>, <etal/></person-group> <article-title>Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer</article-title> <source>N Engl J Med</source> <year>1999</year> <volume>340</volume> <fpage>1137</fpage><lpage>43</lpage></element-citation></ref>
<ref id="b18-jgo-29-e83"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname> <given-names>SY</given-names></name> <name><surname>Lee</surname> <given-names>WM</given-names></name> <name><surname>Kim</surname> <given-names>K</given-names></name> <name><surname>Park</surname> <given-names>SI</given-names></name> <name><surname>Kim</surname> <given-names>BJ</given-names></name> <name><surname>Kim</surname> <given-names>MH</given-names></name>, <etal/></person-group> <article-title>Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer</article-title> <source>Int J Radiat Oncol Biol Phys</source> <year>2011</year> <volume>81</volume> <fpage>e577</fpage><lpage>81</lpage></element-citation></ref>
<ref id="b19-jgo-29-e83"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname> <given-names>JA</given-names></name> <name><surname>Rusthoven</surname> <given-names>C</given-names></name> <name><surname>DeWitt</surname> <given-names>PE</given-names></name> <name><surname>Davidson</surname> <given-names>SA</given-names></name> <name><surname>Schefter</surname> <given-names>TE</given-names></name> <name><surname>Fisher</surname> <given-names>CM</given-names></name></person-group> <article-title>Are we appropriately selecting therapy for patients with cervical cancer? Longitudinal patterns-of-care analysis for stage IB&#x2013;IIB cervical cancer</article-title> <source>Int J Radiat Oncol Biol Phys</source> <year>2014</year> <volume>90</volume> <fpage>786</fpage><lpage>93</lpage></element-citation></ref>
<ref id="b20-jgo-29-e83"><label>20</label><element-citation publication-type="other"><collab>National Comprehensive Cancer Network</collab> <source>NCCN clinical practice guidelines in oncology (cervical cancer) [Internet]</source> <comment>Fort Washington, PA: National Comprehensive Cancer Network; [cited 2017 Jun 30]. Available from:</comment> <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccn.org/professionals/physician_gls/f_guidelines.asp">https://www.nccn.org/professionals/physician_gls/f_guidelines.asp</ext-link></element-citation></ref>
<ref id="b21-jgo-29-e83"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitney</surname> <given-names>CW</given-names></name> <name><surname>Sause</surname> <given-names>W</given-names></name> <name><surname>Bundy</surname> <given-names>BN</given-names></name> <name><surname>Malfetano</surname> <given-names>JH</given-names></name> <name><surname>Hannigan</surname> <given-names>EV</given-names></name> <name><surname>Fowler</surname> <given-names>WC</given-names> <suffix>Jr</suffix></name>, <etal/></person-group> <article-title>Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB&#x2013;IVA carcinoma of the cervix with negative paraaortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study</article-title> <source>J Clin Oncol</source> <year>1999</year> <volume>17</volume> <fpage>1339</fpage><lpage>48</lpage></element-citation></ref>
<ref id="b22-jgo-29-e83"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname> <given-names>PG</given-names></name> <name><surname>Bundy</surname> <given-names>BN</given-names></name> <name><surname>Watkins</surname> <given-names>EB</given-names></name> <name><surname>Thigpen</surname> <given-names>JT</given-names></name> <name><surname>Deppe</surname> <given-names>G</given-names></name> <name><surname>Maiman</surname> <given-names>MA</given-names></name>, <etal/></person-group> <article-title>Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer</article-title> <source>N Engl J Med</source> <year>1999</year> <volume>340</volume> <fpage>1144</fpage><lpage>53</lpage></element-citation></ref>
<ref id="b23-jgo-29-e83"><label>23</label><element-citation publication-type="book"><collab>Japan Society of Obstetrics and Gynecology</collab> <source>The annual report of cervical cancer patients 2008 [Internet]</source> <publisher-loc>Tokyo</publisher-loc> <publisher-name>Japan Society of Obstetrics and Gynecology</publisher-name> <year>2008</year> <comment>[cited 2017 Jun 30]. Available from:</comment> <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://plaza.umin.ac.jp/&#x223C;jsog-go/kanja_2008.pdf">http://plaza.umin.ac.jp/&#x223C;jsog-go/kanja_2008.pdf</ext-link></element-citation></ref>
<ref id="b24-jgo-29-e83"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname> <given-names>Y</given-names></name> <name><surname>Furusawa</surname> <given-names>A</given-names></name> <name><surname>Kitagawa</surname> <given-names>R</given-names></name> <name><surname>Tokinaga</surname> <given-names>A</given-names></name> <name><surname>Ito</surname> <given-names>F</given-names></name> <name><surname>Ukita</surname> <given-names>M</given-names></name>, <etal/></person-group> <article-title>Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan</article-title> <source>J Gynecol Oncol</source> <year>2016</year> <volume>27</volume> <fpage>e29</fpage></element-citation></ref>
<ref id="b25-jgo-29-e83"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname> <given-names>K</given-names></name> <name><surname>Shimada</surname> <given-names>M</given-names></name> <name><surname>Aoki</surname> <given-names>Y</given-names></name> <name><surname>Sakamoto</surname> <given-names>M</given-names></name> <name><surname>Takeshima</surname> <given-names>N</given-names></name> <name><surname>Fujiwara</surname> <given-names>H</given-names></name>, <etal/></person-group> <article-title>Comparison of adjuvant therapy for node-positive clinical stage IB&#x2013;IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation</article-title> <source>Int J Cancer</source> <year>2017</year> <volume>141</volume> <fpage>1042</fpage><lpage>51</lpage></element-citation></ref>
<ref id="b26-jgo-29-e83"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toita</surname> <given-names>T</given-names></name> <name><surname>Kodaira</surname> <given-names>T</given-names></name> <name><surname>Shinoda</surname> <given-names>A</given-names></name> <name><surname>Uno</surname> <given-names>T</given-names></name> <name><surname>Akino</surname> <given-names>Y</given-names></name> <name><surname>Mitsumori</surname> <given-names>M</given-names></name>, <etal/></person-group> <article-title>Patterns of radiotherapy practice for patients with cervical cancer (1999&#x2013;2001): patterns of care study in Japan</article-title> <source>Int J Radiat Oncol Biol Phys</source> <year>2008</year> <volume>70</volume> <fpage>788</fpage><lpage>94</lpage></element-citation></ref>
<ref id="b27-jgo-29-e83"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname> <given-names>RE</given-names></name> <name><surname>Chang</surname> <given-names>J</given-names></name> <name><surname>Ziogas</surname> <given-names>A</given-names></name> <name><surname>Anton-Culver</surname> <given-names>H</given-names></name></person-group> <article-title>Adherence to treatment guidelines for ovarian cancer as a measure of quality care</article-title> <source>Obstet Gynecol</source> <year>2013</year> <volume>121</volume> <fpage>1226</fpage><lpage>34</lpage></element-citation></ref>
</ref-list>
<sec sec-type="display-objects">
<title>Tables</title>
<table-wrap id="t1-jgo-29-e83" position="float">
<label>Table 1.</label>
<caption xml:lang="en"><p>Patient demography analysed using the HBCR and the DPC (n&#x003D;15,163)</p></caption>
<table frame="hsides" rules="all">
<thead>
<tr>
<th valign="top" align="left">Variables</th>
<th valign="top" align="center">Values</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Age, mean (SD)</td>
<td valign="top" align="center">45.1 (15.0)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;&#x003C;20</td>
<td valign="top" align="center">13 (0.1)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;20&#x2013;29</td>
<td valign="top" align="center">1,528 (10.1)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;30&#x2013;39</td>
<td valign="top" align="center">5,041 (33.2)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;40&#x2013;49</td>
<td valign="top" align="center">4,113 (27.1)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;50&#x2013;59</td>
<td valign="top" align="center">1,614 (10.6)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;&#x2265;60</td>
<td valign="top" align="center">2,854 (18.8)</td>
</tr>
<tr>
<td valign="top" align="left">Histology type<sup><xref ref-type="table-fn" rid="table1-fn2-jgo-29-e83">&#x002A;</xref></sup></td>
<td valign="top" align="center">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Squamous cell carcinoma</td>
<td valign="top" align="center">13,314 (87.8)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;&#x2003;Squamous cell carcinoma in situ</td>
<td valign="top" align="center">9,092</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Adenocarcinoma</td>
<td valign="top" align="center">1,371 (9.0)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;&#x2003;Adenocarcinoma in situ</td>
<td valign="top" align="center">296</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Other</td>
<td valign="top" align="center">478 (3.1)</td>
</tr>
<tr>
<td valign="top" align="left">FIGO stage</td>
<td valign="top" align="center">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;I</td>
<td valign="top" align="center">2,288 (15.1)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;II</td>
<td valign="top" align="center">1,314 (8.7)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;III</td>
<td valign="top" align="center">552 (3.6)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;IV</td>
<td valign="top" align="center">780 (5.1)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Unknown<sup><xref ref-type="table-fn" rid="table1-fn3-jgo-29-e83">&#x2020;</xref></sup></td>
<td valign="top" align="center">806 (5.3)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Tis<sup><xref ref-type="table-fn" rid="table1-fn4-jgo-29-e83">&#x2021;</xref></sup></td>
<td valign="top" align="center">9,423 (62.1)</td>
</tr>
<tr>
<td valign="top" align="left">First-line treatment</td>
<td valign="top" align="center">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Surgery</td>
<td valign="top" align="center">10,129 (66.8)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Radiotherapy</td>
<td valign="top" align="center">743 (4.9)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Chemotherapy</td>
<td valign="top" align="center">167 (1.1)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Surgery&#x002B;chemotherapy</td>
<td valign="top" align="center">672 (4.4)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Radiotherapy&#x002B;chemotherapy<sup><xref ref-type="table-fn" rid="table1-fn5-jgo-29-e83">&#x00A7;</xref></sup></td>
<td valign="top" align="center">1,261 (8.3)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Other</td>
<td valign="top" align="center">2,191 (14.4)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table1-fn1-jgo-29-e83"><p>Values are presented as mean (SD) or number (&#x0025;). CCRT, concurrent chemotherapy and radiation therapy; CIN3, cervical intraepithelial neoplasia 3; DPC, Diagnosis Procedure Combination; FIGO, International Federation of Gynecology and Obstetrics; HBCR, Hospital-Based Cancer Registry; ICD-O-3, International Classification of Diseases Oncology 3rd edition; SD, standard deviation.</p></fn>
<fn id="table1-fn2-jgo-29-e83"><label>&#x002A;</label><p>The number of patients in each category was extracted using ICD-O-3 codes;</p></fn>
<fn id="table1-fn3-jgo-29-e83"><label>&#x2020;</label><p>In HBCR, the category includes patients who were resected before definitive diagnoses;</p></fn>
<fn id="table1-fn4-jgo-29-e83"><label>&#x2021;</label><p>Although &#x201C;Tis&#x201D; is not included in the FIGO system, patients with CIN3 and adenocarcinoma in situ were extracted from this stage using ICD-O-3 codes. Further description of stage was refrained due to the complicated nature of code extraction;</p></fn>
<fn id="table1-fn5-jgo-29-e83"><label>&#x00A7;</label><p>Those who have received both radiation therapy and chemotherapy regardless of time gaps between treatments (includes CCRT).</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t2-jgo-29-e83" position="float">
<label>Table 2.</label>
<caption xml:lang="en"><p>Adherence rates for various QIs</p></caption>
<table frame="hsides" rules="all">
<thead>
<tr>
<th valign="top" align="left">QIs</th>
<th valign="top" align="center">Target patients (denominator)</th>
<th valign="top" align="center">Specified care (numerator)</th>
<th valign="top" align="center">No.</th>
<th valign="top" align="center">Adherence rate (95&#x0025; CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">QI1<sup><xref ref-type="table-fn" rid="table2-fn2-jgo-29-e83">&#x002A;</xref></sup></td>
<td valign="top" align="left">Conization for CIN3</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">CIN3 patients who are under age 43 years</td>
<td valign="top" align="left">Patients who had total hysterectomy without conization</td>
<td valign="top" align="left">242/6,256</td>
<td valign="top" align="left">3.9&#x0025; (3.4&#x2013;4.4)</td>
</tr>
<tr>
<td valign="top" align="left">QI2</td>
<td valign="top" align="left">Total hysterectomy for adenocarcinoma in situ</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">Patients who had adenocarcinoma in situ over age 44 years</td>
<td valign="top" align="left">Patients who had total hysterectomy as the last treatment</td>
<td valign="top" align="left">81/93</td>
<td valign="top" align="left">87.1&#x0025; (78.5&#x2013;93.2)</td>
</tr>
<tr>
<td valign="top" align="left">QI3</td>
<td valign="top" align="left">Radical hysterectomy for stage II adenocarcinoma</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">Stage II adenocarcinoma patients</td>
<td valign="top" align="left">Patients who had radical hysterectomy</td>
<td valign="top" align="left">115/170</td>
<td valign="top" align="left">67.6&#x0025; (60.1&#x2013;74.6)</td>
</tr>
<tr>
<td valign="top" align="left">QI4</td>
<td valign="top" align="left">CCRT as the first-line treatment for stage III or IVA</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">Stage III or IVA patients</td>
<td valign="top" align="left">Patients who had CCRT as the first-line treatment</td>
<td valign="top" align="left">397/720</td>
<td valign="top" align="left">55.1&#x0025; (51.4&#x2013;58.8)</td>
</tr>
<tr>
<td valign="top" align="left">QI5</td>
<td valign="top" align="left">CCRT using cisplatin for stage III or IVA</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">Stage III or IVA patients who had CCRT</td>
<td valign="top" align="left">Patients who had cisplatin-based regimen for CCRT</td>
<td valign="top" align="left">333/417</td>
<td valign="top" align="left">79.9&#x0025; (75.7&#x2013;83.6)</td>
</tr>
<tr>
<td valign="top" align="left">QI6<sup><xref ref-type="table-fn" rid="table2-fn2-jgo-29-e83">&#x002A;</xref></sup></td>
<td valign="top" align="left">Chemotherapy for stage III or IVA</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">Stage III or IVA patients who had curative radiation therapy</td>
<td valign="top" align="left">Patients who had chemotherapy before the main</td>
<td valign="top" align="left">8/663</td>
<td valign="top" align="left">1.2&#x0025; (0.5&#x2013;2.4)</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">or CCRT as main treatment</td>
<td valign="top" align="left">treatment</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">QI7</td>
<td valign="top" align="left">Chemotherapy using platinum for stage IVB</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">Stage IVB patients who had chemotherapy</td>
<td valign="top" align="left">Patients who had platinum-based chemotherapy</td>
<td valign="top" align="left">422/426</td>
<td valign="top" align="left">99.1&#x0025; (97.6&#x2013;99.7)</td>
</tr>
<tr>
<td valign="top" align="left">QI8</td>
<td valign="top" align="left">Cystoscope or proctoscope for stage IVA</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">Stage IVA patients</td>
<td valign="top" align="left">Patients who had cystoscope or proctoscope before the treatment</td>
<td valign="top" align="left">87/174</td>
<td valign="top" align="left">50.0&#x0025; (42.3&#x2013;57.7)</td>
</tr>
<tr>
<td valign="top" align="left">QI9</td>
<td valign="top" align="left">Curative radiation therapy using brachytherapy</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">Patients who had curative radiation therapy without surgery</td>
<td valign="top" align="left">Patients who had brachytherapy</td>
<td valign="top" align="left">1,211/1,536</td>
<td valign="top" align="left">78.8&#x0025; (76.7&#x2013;80.9)</td>
</tr>
<tr>
<td valign="top" align="left">QI10<sup><xref ref-type="table-fn" rid="table2-fn2-jgo-29-e83">&#x002A;</xref></sup></td>
<td valign="top" align="left"><sup><xref ref-type="table-fn" rid="table2-fn2-jgo-29-e83">&#x002A;</xref></sup> Post-treatment maintenance therapy using oral</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">chemotherapy</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">Stage I or II patients who had surgery, radiation or CCRT for the first time.</td>
<td valign="top" align="left">Patients who used oral chemotherapy</td>
<td valign="top" align="left">28/2,313</td>
<td valign="top" align="left">1.2&#x0025; (0.8&#x2013;1.7)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table2-fn1-jgo-29-e83"><p>CI, confidence interval; CIN3, cervical intraepithelial neoplasia 3; CCRT, concurrent chemotherapy and radiation therapy; QI, quality indicator.</p></fn>
<fn id="table2-fn2-jgo-29-e83"><label>&#x002A;</label><p>Treatment modality defined as not recommended.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t3-jgo-29-e83" position="float">
<label>Table 3.</label>
<caption xml:lang="en"><p>Adherence rates for PCIs</p></caption>
<table frame="hsides" rules="all">
<thead>
<tr>
<th valign="top" align="left">PCIs</th>
<th valign="top" align="center">Target patients (denominator)</th>
<th valign="top" align="center">Specified care (numerator)</th>
<th valign="top" align="center">No.</th>
<th valign="top" align="center">Adherence rate (95&#x0025; CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">PCI1</td>
<td valign="top" align="left">Total hysterectomy for CIN3</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">CIN3 patients who are over age 50 years</td>
<td valign="top" align="left">Patients who had total hysterectomy</td>
<td valign="top" align="left">562/1,188</td>
<td valign="top" align="left">47.3&#x0025; (44.4&#x2013;50.2)</td>
</tr>
<tr>
<td valign="top" align="left">PCI2</td>
<td valign="top" align="left">Post-operative CCRT for pN1</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">pN1 patients who had surgery without preoperative</td>
<td valign="top" align="left">Patients who had post-operative CCRT</td>
<td valign="top" align="left">163/368</td>
<td valign="top" align="left">44.3&#x0025; (39.1&#x2013;49.5)</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">chemotherapy</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td colspan="2">JSGO guideline recommendation for the denominator population: CCRT</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">PCI3</td>
<td valign="top" align="left">Post-operative therapy for pN1</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">pN1 patients who had surgery without preoperative</td>
<td valign="top" align="left">Patients who had adjuvant chemotherapy without CCRT as</td>
<td valign="top" align="left">162/349</td>
<td valign="top" align="left">46.4&#x0025; (41.1&#x2013;51.8)</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">chemotherapy</td>
<td valign="top" align="left">post-operative therapy</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td colspan="2">JSGO guideline recommendation for the denominator population: CCRT</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">PCI4</td>
<td valign="top" align="left">Post-operative therapy for pN0 or pT1</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">pN0 or pT1 patients who had surgery without preoperative</td>
<td valign="top" align="left">Patients who had adjuvant chemotherapy without CCRT as</td>
<td valign="top" align="left">248/469</td>
<td valign="top" align="left">52.9&#x0025; (48.2&#x2013;57.5)</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">chemotherapy</td>
<td valign="top" align="left">post-operative therapy</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">&#x00A0;</td>
<td colspan="2">JSGO guideline recommendation for the denominator population: radiation therapy (CCRT)</td>
<td valign="top" align="left">&#x00A0;</td>
<td valign="top" align="left">&#x00A0;</td>
</tr>
<tr>
<td valign="top" align="left">CI, co Onco</td>
<td valign="top" align="left">onfidence interval; CIN3, cervical intraepithelial neoplasia 3 ology; PCI, pattern-of-care item.</td>
<td valign="top" align="left">3; CCRT, concurrent chemotherapy and radiation therapy; J</td>
<td valign="top" align="left">SGO, Japan S</td>
<td valign="top" align="left">Society of Gynaecologic</td></tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="t4-jgo-29-e83" position="float">
<label>Table 4.</label>
<caption xml:lang="en"><p>Reasons for non-adherence to specified care<sup><xref ref-type="table-fn" rid="table4-fn2-jgo-29-e83">&#x002A;</xref></sup> (47 hospitals)</p></caption>
<table frame="hsides" rules="all">
<thead>
<tr>
<th rowspan="2" valign="top" align="left">QI</th>
<th rowspan="2" valign="top" align="center">QI descriptor</th>
<th rowspan="2" valign="top" align="center">No. of patients</th>
<th rowspan="2" valign="top" align="center">QI score (&#x0025;)</th>
<th valign="top" align="center" colspan="5">Sufficient reasons (&#x0025;)</th>
<th valign="top" align="center">Insufficient reasons (&#x0025;)</th>
</tr>
<tr>
<th valign="top" align="center">Comorbidities</th>
<th valign="top" align="center">Referral</th>
<th valign="top" align="center">Patient preference</th>
<th valign="top" align="center">Errors in data</th>
<th valign="top" align="center">Other</th>
<th valign="top" align="center">Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">QI3</td>
<td valign="top" align="left">Radical hysterectomy for stage II adenocarcinoma</td>
<td valign="top" align="center">12</td>
<td valign="top" align="center">67.7</td>
<td valign="top" align="center">41.2</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">8.3</td>
<td valign="top" align="center">8.3</td>
<td valign="top" align="center">16.7</td>
<td valign="top" align="center">25.0</td>
</tr>
<tr>
<td valign="top" align="left">QI4</td>
<td valign="top" align="left">CCRT as the first-line treatment for stage III or IVA</td>
<td valign="top" align="center">66</td>
<td valign="top" align="center">55.1</td>
<td valign="top" align="center">63.6</td>
<td valign="top" align="center">6.1</td>
<td valign="top" align="center">12.1</td>
<td valign="top" align="center">3</td>
<td valign="top" align="center">6.1</td>
<td valign="top" align="center">9.1</td>
</tr>
<tr>
<td valign="top" align="left">QI5</td>
<td valign="top" align="left">CCRT using cisplatin for stage III or IVA</td>
<td valign="top" align="center">15</td>
<td valign="top" align="center">79.9</td>
<td valign="top" align="center">66.7</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">6.7</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">26.6</td>
</tr>
<tr>
<td valign="top" align="left">QI8</td>
<td valign="top" align="left">Cystoscope or proctoscope for stage IVA</td>
<td valign="top" align="center">14</td>
<td valign="top" align="center">50.0</td>
<td valign="top" align="center">7.1</td>
<td valign="top" align="center">14.3</td>
<td valign="top" align="center">7.1</td>
<td valign="top" align="center">7.1</td>
<td valign="top" align="center">7.1</td>
<td valign="top" align="center">57.1</td>
</tr>
<tr>
<td valign="top" align="left">QI9</td>
<td valign="top" align="left">Curative radiation therapy using brachytherapy</td>
<td valign="top" align="center">59</td>
<td valign="top" align="center">78.8</td>
<td valign="top" align="center">30.5</td>
<td valign="top" align="center">18.6</td>
<td valign="top" align="center">6.8</td>
<td valign="top" align="center">1.7</td>
<td valign="top" align="center">30.5</td>
<td valign="top" align="center">11.9</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table4-fn1-jgo-29-e83"><p>CCRT, concurrent chemotherapy and radiation therapy; QI, quality indicator.</p></fn>
<fn id="table4-fn2-jgo-29-e83"><label>&#x002A;</label><p>Reasons cited for less than 10 patients were excluded from the list.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</back>
</article>